Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.
Diawara H. et al, (2025), BMJ global health, 10
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10
Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study.
Hamilton F. et al, (2024), The Lancet. Microbe
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.
Arunachalam PS. et al, (2024), Sci Transl Med, 16
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response
Mentzer AJ. et al, (2024), Nature Medicine, 30, 1384 - 1394
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Lv X. et al, (2024), iScience, 27
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), Lancet Infect Dis
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.
Chong AY. et al, (2024), American journal of human genetics, 111, 295 - 308
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544
Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture
Schurz H. et al, (2024), eLife, 13
Mexican Biobank advances population and medical genomics of diverse ancestries.
Sohail M. et al, (2023), Nature
Injectable core-shell microspheres deliver prime-boost immunisation in a single shot
Guyon R. et al, (2023)